Recent Advancements on Long COVID in China: A Narrative Review

References

• Caldera-Crespo LA, Paidas MJ, Roy S, et al. Experimental models of COVID-19. Front Cell Infect Microbiol. 2022;11:792584. doi:10.3389/fcimb.2021.792584
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–758. doi:10.1136/postgradmedj-2020-138234
   PubMed Web of Science ®Google Scholar
• Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146. doi:10.1038/s41579-022-00846-2
   PubMed Web of Science ®Google Scholar
• Chinese Center For Disease Control And Prevention. National novel coronavirus infection epidemic situation; 2023. Available from: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/t20230225_263964.html. Accessed February 25, 2023.
   Google Scholar
• Tan H, Liu J, Zeng F. China needs a scientific long COVID recovery-support platform. Lancet. 2023;401(10374):344–345. doi:10.1016/S0140-6736(23)00138-1
   PubMed Web of Science ®Google Scholar
• World Health Organization. Post COVID-19 condition (Long COVID). Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition. Accessed December 07, 2022.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020.
   Google Scholar
• covid.gov. What is Long COVID? Available from: https://www.covid.gov/longcovid/definitions. Accessed June 14, 2023.
   Google Scholar
• Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593–1607. doi:10.1093/infdis/jiac136
   PubMed Web of Science ®Google Scholar
• Wong MC, Huang J, Wong YY, et al. Epidemiology, symptomatology, and risk factors for long COVID symptoms: population-based, multicenter study. JMIR Public Health Surveill. 2023;9:e42315. doi:10.2196/42315
   PubMedGoogle Scholar
• Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. Int J Biol Sci. 2022;18(12):4768–4780. doi:10.7150/ijbs.75056
   PubMed Web of Science ®Google Scholar
• Garg M, Maralakunte M, Garg S, et al. The conundrum of ‘long-COVID-19’: a narrative review. Int J Gen Med. 2021;14:2491–2506. doi:10.2147/IJGM.S316708
   PubMed Web of Science ®Google Scholar
• Nabavi N. Long covid: how to define it and how to manage it. BMJ. 2020;370:m3489. doi:10.1136/bmj.m3489
   PubMed Web of Science ®Google Scholar
• Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10(9):863–876. doi:10.1016/S2213-2600(22)00126-6
   PubMed Web of Science ®Google Scholar
• Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–631. doi:10.1038/s41591-021-01292-y
   PubMed Web of Science ®Google Scholar
• Bull-Otterson L, Baca S, Saydah S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years - United States, March 2020-November 2021. Morb Morta Weekly Rep. 2022;71(21):713. doi:10.15585/mmwr.mm7121e1
   Web of Science ®Google Scholar
• Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022;28(7):955–972. doi:10.1016/j.cmi.2022.02.018
   PubMed Web of Science ®Google Scholar
• Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019
   PubMedGoogle Scholar
• l-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461–1467. doi:10.1038/s41591-022-01840-0
   PubMed Web of Science ®Google Scholar
• Cutler DM. The Costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809. doi:10.1001/jamahealthforum.2022.1809
   PubMedGoogle Scholar
• Hu F, Zhao Y, Li M, et al. Adverse effects of long COVID and its countermeasures: a review. Chin J Public Health. 2022;38(09):1229–1232.
   Google Scholar
• Liang L, Yang B, Jiang N, et al. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. 2020;35(47):e418. doi:10.3346/jkms.2020.35.e418
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang F, Shen Y, et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021;4(9):e2127403. doi:10.1001/jamanetworkopen.2021.27403
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang W, Shi X, et al. Seroepidemiology of pertussis in the east of China: estimates of incidence of infection in adolescents and adults pre- and post-COVID-19. Front Public Health. 2022;10:1054617. doi:10.3389/fpubh.2022.1054617
   PubMed Web of Science ®Google Scholar
• Tang YF, Han JY, Ren AM, et al. Assessment of long-term effects on pulmonary functions between severe and non-severe convalescent COVID-19 patients: a single-center study in China. J Inflamm Res. 2022;15:4751–4761. doi:10.2147/JIR.S371283
   PubMed Web of Science ®Google Scholar
• Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232. doi:10.1016/S0140-6736(20)32656-8
   PubMed Web of Science ®Google Scholar
• Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021;2021:21250617 doi:10.1101/2021.01.27.21250617.
   Google Scholar
• Ju N, Yang X, Ma X, et al. Hospitalization, interpersonal and personal factors of social anxiety among COVID-19 survivors at the six-month follow-up after hospital treatment: the minority stress model. Eur J Psychotraumatol. 2022;13(1):2019980. doi:10.1080/20008198.2021.2019980
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhao YJ, Zhang QE, et al. COVID-19-related stigma and its sociodemographic correlates: a comparative study. Global Health. 2021;17(1):54. doi:10.1186/s12992-021-00705-4
   PubMed Web of Science ®Google Scholar
• Xiao X, Yang X, Zheng W, et al. Depression, anxiety and post-traumatic growth among COVID-19 survivors six-month after discharge. Eur J Psychotraumatol. 2022;13(1):2055294. doi:10.1080/20008198.2022.2055294
   PubMed Web of Science ®Google Scholar
• Mei Z, Wu X, Zhang X, et al. The occurrence and risk factors associated with post-traumatic stress disorder among discharged COVID-19 patients in Tianjin, China. Brain Behav. 2022;12(2):e2492. doi:10.1002/brb3.2492
   PubMed Web of Science ®Google Scholar
• Fu L, Fang Y, Luo D, et al. Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: cross-sectional survey in five cities in China. BJPsych Open. 2021;7(6):e191. doi:10.1192/bjo.2021.1008
   PubMed Web of Science ®Google Scholar
• Liu YH, Wang YR, Wang QH, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Mol Neurodegener. 2021;16(1):48. doi:10.1186/s13024-021-00469-w
   PubMed Web of Science ®Google Scholar
• Shang YF, Liu T, Yu JN, et al. Half-year follow-up of patients recovering from severe COVID-19: analysis of symptoms and their risk factors. J Intern Med. 2021;290(2):444–450. doi:10.1111/joim.13284
   PubMed Web of Science ®Google Scholar
• Weng J, Li Y, Li J, et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol. 2021;6(5):344–346. doi:10.1016/S2468-1253(21)00076-5
   PubMed Web of Science ®Google Scholar
• General Office of the National Health Commission(China), Rehabilitation Program for discharged COVID-19 Patients (Trial). Available from: http://www.nhc.gov.cn/xcs/zhengcwj/202003/d4558d2cc35e44d5b9adba7c911e0b4c.shtml. Accessed March 4, 2020.
   Google Scholar
• Kim Y, Kim SE, Kim T, et al. Preliminary guidelines for the clinical evaluation and management of long COVID. Infect Chemother. 2022;54(3):566–597. doi:10.3947/ic.2022.0141
   PubMed Web of Science ®Google Scholar
• Mandal S, Barnett J, Brill SE, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396–398. doi:10.1136/thoraxjnl-2020-215818
   PubMed Web of Science ®Google Scholar
• Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13(1):446. doi:10.1038/s41467-021-27797-1
   PubMed Web of Science ®Google Scholar
• Liao B, Liu Z, Tang L, et al. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. Int J Med Sci. 2021;18(1):29–41. doi:10.7150/ijms.49728
   PubMed Web of Science ®Google Scholar
• Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. doi:10.1016/j.eclinm.2020.100463
   PubMedGoogle Scholar
• Marvisi M, Ferrozzi F, Balzarini L, Mancini C, Ramponi S, Uccelli M. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution. Int J Infect Dis. 2020;99:485–488. doi:10.1016/j.ijid.2020.08.054
   PubMed Web of Science ®Google Scholar
• Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210–216. doi:10.1038/s41590-021-01113-x
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Patil S, Subramaniam N, Sharma R. COVID-19 vaccine hesitancy and resistance in India explored through a population-based longitudinal survey. Vaccines. 2021;9(10):1064. doi:10.3390/vaccines9101064
   Web of Science ®Google Scholar
• Brannock MD, Chew RF, Preiss AJ, et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun. 2023;14(1):2914. doi:10.1038/s41467-023-38388-7
   PubMed Web of Science ®Google Scholar
• Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(19):12422. doi:10.3390/ijerph191912422
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. The dynamics of epidemic prevention and control. Available from: http://www.nhc.gov.cn/xcs/yqfkdt/202109/bf2cf785ce0544ae818a76ffbb18ca79.shtml. Accessed September 19, 2021.
   Google Scholar
• Umakanthan S, Bukelo MM, Gajula SS. The Commonwealth Caribbean COVID-19: regions resilient pathway during pandemic. Front Public Health. 2022;10:844333. doi:10.3389/fpubh.2022.844333
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Lawrence S. Predictors of COVID-19 vaccine hesitancy in Germany: a cross-sectional, population-based study. Postgrad Med J. 2022;98(1164):756–764. doi:10.1136/postgradmedj-2021-141365
   PubMed Web of Science ®Google Scholar
• Wang S, Li Y, Yue Y, et al. Adherence to healthy lifestyle prior to infection and risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(3):232–241. doi:10.1001/jamainternmed.2022.6555
   PubMed Web of Science ®Google Scholar
• Li J, Xia W, Zhan C, et al. A telerehabilitation programme in post-discharge COVID-19 patients (TERECO): a randomised controlled trial. Thorax. 2022;77(7):697–706. doi:10.1136/thoraxjnl-2021-217382
   PubMed Web of Science ®Google Scholar
• Liu Z, Qiao D, Xu Y, et al. The efficacy of computerized cognitive behavioral therapy for depressive and anxiety symptoms in patients with COVID-19: randomized controlled trial. J Med Internet Res. 2021;23(5):e26883. doi:10.2196/26883
   PubMed Web of Science ®Google Scholar
• Li J, Li X, Jiang J, et al. The effect of cognitive behavioral therapy on depression, anxiety, and stress in patients with COVID-19: a randomized controlled trial. Front Psychiatry. 2020;11:580827. doi:10.3389/fpsyt.2020.580827
   PubMedGoogle Scholar
• He Y, Yang L, Zhu X, et al. Mental health chatbot for young adults with depressive symptoms during the COVID-19 pandemic: single-blind, three-arm randomized controlled trial. J Med Internet Res. 2022;24(11):e40719. doi:10.2196/40719
   PubMed Web of Science ®Google Scholar
• Bramante C, Buse JB, Liebovitz D, et al. Outpatient treatment of COVID-19 and the development of long COVID Over 10 Months: A multi-center, quadruple-blind, parallel group randomized phase 3 trial. Lancet. 2023.
   Google Scholar
• EINPRESSWIRE. Adult stem cell therapy for COVID-19 sequelae begins in Japan for the first time in the world; 2020. Available from: https://www.einpresswire.com/article/532284733/adult-stem-cell-therapy-for-covid-19-sequelae-begins-in-japan-for-the-first-time-in-the-world. Accessed December 08, 2020.
   Google Scholar
• Shi L, Yuan X, Yao W, et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022;75:103789 doi:10.1016/j.ebiom.2021.103789.
   PubMed Web of Science ®Google Scholar
• Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12(1):11252.
   PubMedGoogle Scholar
• Hawkins J, Hires C, Keenan L, Dunne E. Aromatherapy blend of thyme, Orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: a randomized, double-blinded, placebo controlled clinical trial. Complement Ther Med. 2022;67:102823.
   PubMed Web of Science ®Google Scholar
• D’Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Randomized clinical trial “olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin”: preliminary results. Eur Rev Med Pharmacol Sci. 2021;25(11):4156–4162.
   PubMed Web of Science ®Google Scholar
• Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med. 2022;70(1):61–67. doi:10.1136/jim-2021-002051
   PubMed Web of Science ®Google Scholar
• Pinto MD, Lambert N, Downs CA, et al. Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection. J Nurse Pract. 2022;18(3):335–338 doi:10.1016/j.nurpra.2021.12.016.
   PubMedGoogle Scholar
• Naureen Z, Dautaj A, Nodari S, et al. Proposal of a food supplement for the management of post-COVID syndrome. Eur Rev Med Pharmacol Sci. 2021;25(1 Suppl):67–73 doi:10.26355/eurrev_202112_27335.
   PubMedGoogle Scholar
• Umakanthan S, Senthil S, John S, et al. The effect of statins on clinical outcome among hospitalized patients with COVID-19: a multi-centric cohort study. Front Pharmacol. 2022;13:742273. doi:10.3389/fphar.2022.742273
   PubMed Web of Science ®Google Scholar